US FDA approves Botox Cosmetic to improve the appearance of crow’s feet lines – A new use for Botox Cosmetic (onabotulinumtoxinA) for the temporary improvement in the appearance of moderate to severe lateral canthal lines, known as crow’s feet, in adults is approved in USA. Botox Cosmetic is the only FDA approved drug treatment option for lateral canthal lines.
Botox injections associated with only modest benefit for chronic migraine and daily headaches – Although botulinum toxin A (“Botox”) injections are U.S. Food and Drug Administration approved for preventive treatment for chronic migraines, a review and analysis of previous studies finds a small to modest benefit for patients with chronic migraine headaches and chronic daily headaches, although botox injections were not associated with greater benefit than placebo for preventing episodic migraine or chronic tension-type headaches.
13.8 Million Cosmetic Plastic Surgery Procedures Performed in 2011 – 5 Percent Increase Leads to Second Consecutive Yearly Gain – In US, the plastic surgery market continues to show significant growth – two years in a row. 13.8 million cosmetic plastic surgery procedures (both surgical and minimally-invasive) were performed in the United States in 2011, up 5 percent since 2010. In addition, 5.5 million reconstructive plastic surgery procedures were performed last year, up 5 percent.
Allergan’s BOTOX? Receives A Positive Opinion in Fourteen European Countries for Urinary Incontinence in Patients with MS or Spinal Cord Injury – Allergan is pleased to announce that BOTOX (botulinum toxin type A) has received a positive opinion from the Irish Medicines Board for the management of urinary incontinence in adults with neurogenic detrusor overactivity (NDO) resulting from neurogenic bladder due to stable sub-cervical spinal cord injury, or multiple sclerosis.
Study compares 2 types of botulinum toxin for cosmetic use – Botulinum toxin, a protein long considered harmful, is now known as a neuromodulator (a chemical that affects nerve impulses) that has cosmetic and medical uses. Not all varieties of botulinum toxin seem to be equally effective in reducing crow’s feet wrinkles, according to a report published by Archives of Facial Plastic Surgery, one of the JAMA/Archives journals.
Men fuel rebound in plastic surgery — New ASPS statistics show sizeable increases in facelifts and other surgical procedures for men – More men are going under the knife of cosmetic plastic surgeons. This is revealed in tatistics released by the American Society of Plastic Surgeons (ASPS) of USA.
Allergan Resolves United States Government Investigation of Past Sales and Marketing Practices Relating to Certain Therapeutic Uses of BOTOX(R) – Allergan, Inc. (NYSE: AGN) announced that it has reached a resolution with the United States Department of Justice (DOJ) regarding the previously reported Government investigation into Allergan’s past U.S. sales and marketing practices relating to certain therapeutic uses of BOTOX(R) (onabotulinumtoxinA).
Botulinum toxin injection may help prevent some types of migraine pain – A preliminary study suggests the same type of botulinum injection used for cosmetic purposes may be associated with reduced frequency of migraine headaches that are described as crushing, vicelike or eye-popping (ocular), but not pain that is experienced as a buildup of pressure inside the head.
Aesthetic Medicine has seen a dramatic increase in the diversity of the patients treated over the past decade and this trend is expected to continue to grow stronger than ever, with applications that cater to all people. – The American Society for Aesthetic Plastic Surgery (ASAPS), the leading national organization of board-certified plastic surgeons who specialize in cosmetic surgery, offers its predictions for cosmetic surgery in 2009.
Allergan Announces U.S. Food and Drug Administration (FDA) Approval of LATISSE(TM) — First and Only Treatment Approved by the FDA for Hypotrichosis of Eyelashes. New Prescription Product Increases Length, Thickness and Darkness of Eyelashes. – Allergan, Inc. (NYSE: AGN) announced that the U.S. Food and Drug Administration (FDA) has approved LATISSE(TM) (bimatoprost ophthalmic solution) 0.03% as a novel treatment for hypotrichosis of the eyelashes.